HAE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HAE is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to invest. The stock is near its pivot level, showing a stable entry zone, and the company has fresh product/regulatory catalysts plus improving profitability. While revenue is slightly down, earnings, EPS, and margins are improving, which supports a constructive long-term view. I would classify this as a buy rather than a wait-and-see name.
HAE is trading pre-market around 60.87, very close to its pivot of 60.18 and below first resistance at 61.758. RSI_6 is neutral at 51.833, so the stock is not overbought. MACD histogram is positive at 0.0493 but contracting, which suggests momentum is still supportive but not accelerating strongly. Moving averages are converging, indicating a tightening range and a potential base-building setup. Short-term pattern stats also lean positive, with an estimated 70% chance of a modest next-day rise and stronger upside over the next week and month. Overall, the technical picture is constructive for a long-term entry near current levels.
["FDA expanded labeling for VASCADE MVP XL, widening the addressable market", "Clinical study showed VASCADE MVP XL outperforms VASCADE MVP with zero bleeding complications", "Upcoming HRS 2026 presentation can keep attention on the product pipeline", "Net income, EPS, and gross margin all improved year over year in the latest quarter", "Stock is trading near pivot support, offering a reasonable current entry point"]
["Latest quarter revenue declined 2.75% year over year", "Several analysts have lowered price targets recently", "MACD momentum is positive but contracting, so upside is not sharply accelerating", "No insider buying trend and no notable hedge fund accumulation trend", "No recent congress trading data or influential buyer activity"]
In the latest reported quarter, 2026/Q3, Haemonetics showed mixed but improving fundamentals. Revenue fell to 338.97 million, down 2.75% year over year, but profitability improved meaningfully: net income rose 19.33% to 44.74 million, EPS increased 28.38% to 0.95, and gross margin expanded to 56.47% from prior levels. That combination suggests better operational efficiency even though top-line growth is still soft.
Wall Street is moderately positive but cautious. Recent analyst actions show multiple price target cuts, including Mizuho to $70 from $80 with an Outperform rating, BTIG to $84 from $88 with a Buy rating, and Citi to $64 from $70 with a Neutral rating. The trend is toward lower targets, but the ratings mix still leans constructive overall, with several Outperform/Buy views offset by some Neutral stances. Pros: improving margins and earnings, plus product/regulatory catalysts. Cons: revenue contraction and cautious target revisions. Net: pros slightly outweigh cons for a long-term investor.
